A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients

Pfizer logo

Pfizer

Status

Withdrawn

Conditions

Asthma

Treatments

Drug: Oral Methylprednisolone Tablets

Study type

Observational

Funder types

Industry

Identifiers

NCT00971893
B0121003

Details and patient eligibility

About

The present study is designed to collect data on real world experience on use of Medrol in acute asthma in Indian patients.

Full description

Sequential enrollment

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • To be eligible for enrollment in this study, patients must be prescribed oral Medrol® tablets (4mg and 16 mg) for acute asthma as per the locally approved prescribing information. The prescription of Medrol® will be separated from the decision to include the patient in the study.
  • Medrol® tablets, will be prescribed to the patient by the physician according to his/her usual practice. The decision to prescribe Medrol® tablet will necessarily precede and will be independent of the decision to enroll patient into the study. Only those patients who have been prescribed Medrol® tablets will be evaluated for their potential eligibility for the study
  • Only those patients, who are ready and willing to sign an informed consent, will be included in the study
  • Subject can be contacted through telephone

Exclusion criteria

  • Based upon history or physical exam in the emergency department (ED) or Clinic, subjects with known or suspected cause of pulmonary symptoms other than asthma, such as COPD, CHF, pneumonia, pulmonary embolism, or angioedema
  • Any contraindication to Medrol tablet use. Contraindications of Medrol use are systemic fungal infections and known hypersensitivity to components

Trial design

0 participants in 1 patient group

Methylprednisolone Group
Treatment:
Drug: Oral Methylprednisolone Tablets

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems